Adverum Biotechnologies doses first Wet AMD patient in phase-1 trial
Category: #health  By Pankaj Singh  Date: 2019-06-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Adverum Biotechnologies doses first Wet AMD patient in phase-1 trial

The California-based Adverum Biotechnologies Inc., which caters to the unmet medical requirements in rare and ocular diseases, has announced that it dosed its first wet AMD patient in the second cohort of its OPTIC phase 1 clinical trial for ADVM – 022 gene therapy. Reportedly, patients are receiving a single intravitreal injection of ADVM – 022 with a dosage of 2 x 10 ^11 vg/eye.

As per trusted sources, during the first phase of treatment, 6 patients were given ADVM – 022 at a dose of 6 x 10^11 vg/eye. In the second phase, the patients were given a dosage of 2 x 10^11 vg/eye owing to the strong preliminary anatomical response observed among patients in the first cohort. The primary endpoint of the trial is to test the safety and tolerability of the therapy at 24 weeks after giving the dosage to the patients. Each person undergoing the trial will be carefully monitored for a period of two years.

Arshad M. Khanani, M.A., M.D., trial investigator and director of clinical research department at Sierra Eye Associates, was reportedly quoted stating that ADVM – 022 has the ability to transform the prevailing treatment of neovascular AMD. A more consistent treatment can enhance long-term vision outcomes for patients in clinical practice in addition to alleviating the treatment burden, Khanani added.

For the record, ADVM – 022 uses a trademarked vector capsid (AAV.7m8) – which carries an aflibercept coding sequence – controlled by an expression cassette. It is then delivered as a sole intravitreal administration.

The existing therapy for treating wet AMD is anti-VEGF intravitreal injections. These injections work for a temporary period and need to be taken every 4-8 weeks to maintain vision gains.

Reportedly, eight foremost retinal care centers spread across the United States are anticipated to participate in the OPTIC phase 1 clinical trial of ADVM – 022.

 

Source: http://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-doses-first-patient-second-cohort-optic



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Experian takes over MyHealthDirect for patient engagement and access
Experian takes over MyHealthDirect for patient engagement and access
By Pankaj Singh

  • MyHealthDirect’s easy-to-understand technology guides its patients to profound and right care.
  • Acquisition of MyHealthDirect would strengthen...

Amazon rolls out Scout autonomous delivery robots in California
Amazon rolls out Scout autonomous delivery robots in California
By Pankaj Singh

  • The company brings out its 6-wheeled, sidewalk-driving delivering robot for delivery in the Irvine area of California.
     
  • The driverless...

hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases
hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases
By Pankaj Singh

This clinical study will assess the safety and immunogenicity of vaccine when given with or without adjuvant to small cohorts of healthy subjects.

hVIVO plc has re...